Study on the clinical outcomes of COVID-19 infection and immune responses following the third booster dose of inactivated COVID-19 vaccine in hematologic disease patients
Oct 2026· Frontiers in Public Health· Vol 14· 0 citations· 40 references
TL;DR
Three inactivated vaccine doses were associated with higher NAb and IgG positivity overall and among three-dose recipients, NAb positivity was lower with hematologic diseases than without documented hematologic disease or solid tumors, and intervals were modestly longer with hematologic diseases.
Abstract
Background Patients with hematologic diseases may have impaired immunity owing to their underlying diseases and immunosuppressive treatments. Evidence on documented SARS-CoV-2 RT-PCR outcomes and responses to inactivated COVID-19 vaccines remains limited. Methods This retrospective study analyzed three independently identified populations: 20,813 individuals tested by SARS-CoV-2 RT-PCR, 2,438 tested for anti-SARS-CoV-2 IgG, and 1,946 adults tested after two or three vaccine doses. Intervals to documented RT-PCR negativity were analyzed only among positive individuals with subsequent negative results. Vaccination analyses were adjusted for age, sex, testing interval, and disease group. Monthly comparisons were cross-sectional. Serial antibody measurements were analyzed separately. Results Recorded RT-PCR positivity was lower among tested individuals with hematologic diseases (4.77% vs. 10.74%; p < 0.001). Among 64/64 positive individuals with and 381/2,091 without hematologic diseases who had documented subsequent negative results, median intervals to negativity were 5.05 versus 3.99 days (difference, 1.06 days; 95% CI, 0.73–2.21; p < 0.001). Within the hematologic disease group, longer intervals were observed after prior immunosuppressive treatment (5.99 vs. 3.97 days); haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients had the longest descriptive median interval (6.97 days). In the separate IgG-testing population, positivity did not differ significantly (86.00% vs. 90.16%; p = 0.174). Three versus two doses were associated with higher neutralizing antibody (NAb) positivity (94.1% vs. 77.3%; adjusted prevalence ratio [aPR], 1.281; 95% CI, 1.232–1.332) and IgG positivity (97.2% vs. 83.4%; aPR, 1.229; 95% CI, 1.189–1.271). Among 20 paired participants, 19 had higher NAb levels after the third dose. Among three-dose recipients, NAb positivity was 25/32 (78.13%) with hematologic diseases, 36/42 (85.71%) with solid tumors, and 743/780 (95.26%) without documented hematologic disease or solid tumors (overall p < 0.001). Conclusion Among RT-PCR-positive individuals with documented subsequent negativity, intervals were modestly longer with hematologic diseases. Within this group, median intervals were longer after immunosuppressive treatment, and longest among haploidentical allo-HSCT recipients. Differential availability of negative results warrants caution. Three inactivated vaccine doses were associated with higher NAb and IgG positivity overall. Among three-dose recipients, NAb positivity was lower with hematologic diseases than without documented hematologic disease or solid tumors.
CD4 + T cell responses are an independent correlate of COVID-19 risk among PWH with pre-existing SARS-CoV-2 immunity, and in people with HIV and hybrid immunity, CD4 + T cell responses at one month post-vaccination correlate inversely with risk of COVID-19 over 6 months.
Sharon Khuzwayo, Bo Zhang, Valentin Voillet et al.· Nature Communications· 1 citation
Neutralizing antibodies are a correlate of protection (CoP) of SARS-CoV-2 vaccine efficacy. However, data informing CoPs often explicitly exclude people on immunosuppressive therapies who are at an increased risk of symptomatic and severe COVID-19, delayed viral clearance, and death. Investigating the relationship betw...
E. Stadler, S. R. Khan, K. M. Elias et al.· medRxiv· 0 citations
Background: Immunocompromised patients are at heightened risk for severe COVID-19 and its complications. While vaccination is critical for this population, long-term adherence and the durability of vaccine-induced immunity remain significant public health concerns. This study aimed to evaluate the longitudinal serologi...
A. Sarcone, Maria Rosaria Deodato, A. De Pasquale et al.· Vaccines· 0 citations
Abstract Background Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether 2 coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose. Metho...
H. Chemaitelly, H. Ayoub, P. Coyle et al.· Open Forum Infectious Diseas...· 0 citations
Background People living with HIV (PLWHA) may experience increased vulnerability to SARS‐CoV‐2 infection and severe COVID‐19 due to immune dysregulation, comorbidities, and treatment adherence challenges. Kenya has over 1.4 million PLWHA. However, only a few have been reported with severe COVID‐19, suggesting potential...
James Kinoti Njue, L. Wekesa, Alex Maiyo et al.· AIDS Research and Treatment· 0 citations
Early after household exposure, binding and neutralising antibodies were similar in all participants, but differences in T-cell functional responses were evident in individuals who developed symptoms after SARS-CoV-2 infection.
Christopher Kandel, Jessica A. Breznik, Maureen Taylor et al.· The Lancet Microbe· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.